###begin article-title 0
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inhibition of PP2A by LIS1 increases HIV-1 gene expression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 239 244 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 406 411 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Lissencephaly is a severe brain malformation in part caused by mutations in the LIS1 gene. LIS1 interacts with microtubule-associated proteins, and enhances transport of microtubule fragments. Previously we showed that LIS1 interacts with HIV-1 Tat protein and that this interaction was mediated by WD40 domains of LIS1. In the present study, we analyze the effect of LIS1 on Tat-mediated transcription of HIV-1 LTR.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 363 371 363 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 173 178 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat-mediated HIV-1 transcription was upregulated in 293 cells transfected with LIS1 expression vector. The WD5 but not the N-terminal domain of LIS1 increases Tat-dependent HIV-1 transcription. The effect of LIS1 was similar to the effect of okadaic acid, an inhibitor of protein phosphatase 2A (PP2A). We then analyzed the effect of LIS1 on the activity of PP2A in vitro. We show that LIS1 and its isolated WD5 domain but not the N-terminal domain of LIS1 blocks PP2A activity.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results show that inhibition of PP2A by LIS1 induces HIV-1 transcription. Our results also point to a possibility that LIS1 might function in the cells as a yet unrecognized regulatory subunit of PP2A.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1496 1498 1496 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1602 1604 1602 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1605 1607 1605 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1673 1675 1673 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1676 1678 1676 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1856 1858 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1859 1861 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2083 2085 2083 2085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2199 2201 2199 2201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 161 166 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 351 356 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1709 1714 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1835 1840 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1931 1936 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2067 2072 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2178 2183 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tat protein is a transcriptional activator encoded in the genome of HIV-1 (reviewed in [1]). Tat binds to a transactivation response (TAR) RNA [1] and activates HIV-1 transcription by recruiting transcriptional co-activators that include Positive Transcription Elongation Factor b and histone acetyl transferases [2-4]. In addition to its function in HIV-1 transcription, Tat also interacts with a number of cellular factors thus affecting host cellular functions [5,6]. In T cells, Tat causes apoptosis by binding to microtubules and affecting microtubule formation [7]. Tat also causes apoptosis in neurons apparently by changing polarity of the neuronal membranes [8,9]. Previously, we reported that Tat binds to LIS1 [10]. LIS1 is a microtubule binding protein and its mutation causes Lissencephaly, a severe brain malformation [11]. Lissencephaly is caused by abnormal neuronal migration during brain development [12]. LIS1 is 45 kD protein that contains seven WD repeats and an N terminal domain devoid of the repeats. The WD repeats-containing proteins fold into a beta propeller structure that participates in protein-protein interaction in cells [13]. The diverse family of WD40 proteins includes B-subunits of protein phosphatase 2A (PP2A). PP2A is a major serine/threonine phosphatase found mainly in the nucleus but also present in the cytoplasm [14]. PP2A catalytic subunit associates with the A subunit to form the core enzyme, and with the A and B subunits to form the holoenzyme [15]. The B subunits are diversified and represented by a variety of proteins ranging from 45 kD to 55 kD [15-17]. B subunits target PP2A to different locations within the cell [18-20]. PP2A was reported to affect HIV-1 transcription both positively and negatively. Deregulation of cellular enzymatic activity of PP2A inhibited Tat-induced HIV-1 transcription [21,22]. Expression of the catalytic subunit of PP2A enhanced activation of HIV-1 promoter by phorbol myristate acetate (PMA), whereas inhibition of PP2A by okadaic acid and by fostriecin prevented activation of HIV-1 promoter [22]. In contrast, inhibition of PP2A was shown to induce phosphorylation of Sp1 and upregulate HIV-1 transcription [23].
###end p 9
###begin p 10
###xml 486 494 486 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 298 301 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 618 623 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this report, we investigate the effect of LIS1, full length or its isolated domains, on Tat mediated HIV-1 transcription in 293 cells. We compared the effect of LIS1 with the effect of okadaic acid, a known inhibitor of PP2A. We also analyzed the effect of LIS1 on strong viral cytomegalovirus (CMV) promoter and a strong cellular phosphoglycerate kinase (PGK) promoter. Observing similar effects of LIS1 and okadaic acid, we also analyzed the effect of LIS1 on the activity of PP2A in vitro. Our results presented here point to LIS1 as a yet unrecognized regulator of PP2A that may contribute to the regulation of HIV-1 transcription.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LIS1 induces HIV-1 transcription
###end title 12
###begin p 13
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 426 428 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 512 513 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 590 596 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lac Z </italic>
###xml 678 679 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 872 873 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1398 1400 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1466 1472 1449 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lac Z </italic>
###xml 1550 1551 1533 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1654 1659 1637 1642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 1665 1666 1648 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 580 585 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 846 851 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1203 1208 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1456 1461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1644 1649 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1774 1779 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We analyzed the effect of LIS1 overexpression on HIV-1 transcription in 293 cells. Protein level of LIS1 was elevated in the cells transfected with LIS1-expressing vector as compared to the control cells transfected with the empty vector (Fig. 1, panel A lanes 1 and 2). Immunoblotting of tubulin was used as a control for equal protein load (Fig. 1, panel A). We also expressed a Flag-tagged Bgamma-subunit of PP2A (Bgamma) [24] and its expression was verified by immunoblotting with anti-Flag antibodies (Fig. 1, panel B, lane 2). Co-transfection of LIS1 expression vector with HIV-1 LTR-Lac Z and Tat-expression vectors increased Tat-induced transcription in 293 cells (Fig. 1, panel C, compare lanes 3-5 to lane 2). In contrast, co-transfection with the Bgamma subunit of PP2A, which also contains WD40 repeats, did not increase Tat mediated HIV-1 transcription (Fig. 1, panel C, lanes 6 to 8). Although expression of the Bgamma did not have an effect on Tat-induced transcription, we argue that LIS1, a WD40 protein having a structural and amino acid sequence similarity to the PP2A regulatory B-subunit, might still function as a modulator of cellular PP2A. Thus we compared the effect of LIS1 on HIV-1 transcription with the effect of okadaic acid. Okadaic acid specifically inhibits PP2A at low concentration (0.1 - 1 nM) and inhibits both PP1 and PP2A at higher concentration (0.1-1 muM) [25]. Okadaic acid treatment of 293 cells transfected with HIV-1 LTR-Lac Z and Tat expression vectors showed increase in Tat-induced transcription (Fig. 2, panel A). In contrast, okadaic acid had no effect on the expression of the TAR RNA-deleted HIV-1 LTR-LacZ (Fig. 2, panel B). Thus taken together, these results show that in 293 cells both LIS1 and okadaic acid upregulate HIV-1 transcription.
###end p 13
###begin p 14
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LIS1 induces HIV-1 transcription</bold>
###xml 34 36 34 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 34 36 34 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 403 404 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 403 404 395 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 592 597 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 789 793 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ</italic>
###xml 838 843 826 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 13 18 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 582 587 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 685 688 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 828 833 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
LIS1 induces HIV-1 transcription. A and B, 293 cells grown in DMEM to 50% confluency were transfected with a LIS1 expression vector (panel A, lane 1), Flag-Bgamma expression vector (panel B, lane 2) or pCI expression vector. Cells were lysed in SDS-loading buffer. Lysates were resolved on 12% SDS PAGE followed by immunoblotting with anti-LIS1, anti-alpha-tubulin or anti-Flag antibodies as indicated. C, 293 cells were grown to 50% confluency and transfected with different concentrations of vectors expressing LIS1 (lanes 3-5) or Bgamma subunit of PP2A (lanes 6-8) combined with HIV-1 LTR lacZ and Tat expression vectors. The pCI-neo vector was added to keep constant the amount of CMV promoter-containing pCI vector in the transfection. Lane 1, control transfected with only HIV-1 LTR-LacZ. Lane 2, control transfected with HIV-1 LTR-LacZ and Tat expression vectors. Expression of beta-galactosidase was analyzed using ONPG-based assay. The results are expressed as a fold of transactivation.
###end p 14
###begin p 15
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Upregulation of HIV-1 transcription by okadaic acid</bold>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 172 182 172 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(panel A) </bold>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 240 249 240 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(panel B)</bold>
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 207 212 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Upregulation of HIV-1 transcription by okadaic acid. 293 cells were grown to 50% confluency and transfected with a combination of HIV-1 LTR-LacZ and Tat expression vectors (panel A) or TAR deleted mutant of HIV-1 LTR-LacZ expression vector (panel B). Okadaic acid was added in increasing concentrations and the cells were assayed for beta-galactosidase at 48 hours posttransfection. The results are expressed as a fold of transactivation.
###end p 15
###begin title 16
WD5 domain of LIS1 upregulates Tat mediated transcription
###end title 16
###begin p 17
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ </italic>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1495 1497 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1645 1646 1641 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 583 588 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1020 1025 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1190 1195 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1258 1263 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1386 1389 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1476 1479 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1604 1607 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Next we analyzed whether a particular region of LIS1 was responsible for the increase of HIV-1 transcription. Our previous study indicated that Tat interacts with WD5 domain of LIS1 but not with the N-terminal portion of LIS1, which is devoid of the WD40 domains [10]. WD5 and the N terminal domain of LIS1 were expressed in bacteria as fusions with homeodomain-derived cell penetrating peptide to allow uptake of the fused LIS1 domains into the mammalian cells. The expression of WD5 and N-terminal domain of LIS1 was verified by SDS PAGE (Fig. 3A). 293 cells were transfected with HIV-1 LTR-lacZ and Tat-expression vectors and the transfected cells were treated with the cell permeable peptides for 24 hrs following the transfection. Treatment of the transfected cells with WD5 peptide increased Tat-induced transcription (Fig. 3B). In contrast, treatment with the peptide containing N-terminal domain of LIS1 showed no effect on Tat-transactivation (Fig. 3B). The peptides did not have a profound effect on the basal HIV-1 transcription from LTR containing a TAR deletion (Fig. 3C). Taken together, these results suggest that WD5 domain of LIS1 might be responsible for the induction of HIV-1 transcription. To determine whether the effect of LIS1 on the HIV-1 promoter was specific, we transfected 293T cells with vectors expressing EGFP under the control of viral cytomegalovirus (CMV) or cellular phosphoglycerate kinase (PGK) promoters. LIS1 induces transcription from CMV promoter (Fig. 4A) but inhibited transcription from PGK promoter (Fig 4B). In contrast, expression of Bgamma inhibited both CMV and PGK-mediated transcription (Fig. 4).
###end p 17
###begin p 18
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">WD5 domain of LIS1 upregulates Tat mediated HIV-1 transcription</bold>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 65 66 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 131 139 131 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 291 292 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 291 292 291 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 452 453 452 453 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LacZ </italic>
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 131 138 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 321 326 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 498 503 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
WD5 domain of LIS1 upregulates Tat mediated HIV-1 transcription. A. The WD5 domain and N-terminal domain of LIS1 were expressed in E. coli and extracted from the inclusion bodies as described in Methods. The dialyzed peptides were resolved on 12% SDS-PAGE gel and stained by Coumassie blue. B. 293 cells transfected with HIV-1 LTR-LacZ and Tat expression vectors and treated at 24 hrs posttransfection with WD5 domain or the N-terminal domain of LIS1. C, 293 cells transfected with TAR RNA-deleted HIV-1 LTR-LacZ vector and treated as in panel A. The results are presented as a fold of transactivation.
###end p 18
###begin p 19
###xml 106 109 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
293T cells were grown to 50% confluency and transfected with vectors expressing EGFP under the control of CMV (panel A) or PGK (panel B) promoters without or with vectors expressing LIS1 or Bgamma subunit of PP2A. The EGFP expression was measured by fluorescence in the cellular lysates at 480 nm excitation and 510 nm emission as described in Methods.
###end p 19
###begin title 20
The WD5 domain of LIS1 inhibits phosphorylase-phosphatase activity of PP2A
###end title 20
###begin p 21
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 274 276 274 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b </italic>
###xml 314 316 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 324 326 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 334 336 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 361 363 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 537 538 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 628 629 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 834 836 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 1009 1011 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
To determine whether the effect of LIS1 is due to the inhibition PP2A, we analyzed the effect of LIS1 on the phosphorylase phosphatase activity of PP2A. Glycogen phosphorylase-a, a general substrate of PP2A and PP1 phosphatases was prepared by phosphorylating phosphorylase-b with phosphorylase kinase using (gamma32P) ATP [26]. The (32P)-labeled phosphorylase-a was then used as a substrate for PP2A. We also used PP1 as a control. LIS1 inhibited the phosphorylase phosphatase activity of PP2A in a concentration-dependent manner (Fig. 5). In contrast, LIS1 had no effect on the phosphorylase phosphatase activity of PP1 (Fig. 5). When purified peptides containing WD5 or N-terminal domains of LIS1 were used instead of full length LIS1, we observed inhibition of PP2A activity by the WD5 but not the N-terminal domain of LIS1 (Fig. 6A). When the peptides were assayed with PP1, no significant inhibition was observed and the effect of the peptides did not differ at high concentration of the peptides (Fig. 6B). Our results thus indicate that LIS1 might directly inhibit PP2A and that the inhibition of PP2A is likely to be mediated by WD domain(s) of LIS1.
###end p 21
###begin p 22
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LIS1 inhibits PP2A activity <italic>in vitro</italic></bold>
###xml 109 111 109 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
LIS1 inhibits PP2A activity in vitro. Phosphatase assay was performed as described in Methods. Phosphorylase-a substrate, PP1 or PP2A were incubated with indicated concentrations of LIS1 protein. Results are presented as a percent of untreated control
###end p 22
###begin p 23
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">invitro</italic>
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">WD5 of LIS1 inhibits PP2A activity <italic>invitro</italic></bold>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 140 141 140 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 157 158 157 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
WD5 of LIS1 inhibits PP2A activity invitro. Phosphatase assay was performed as described in Methods. Phosphorylase-a substrate, PP2A (panel A) or PP1 (panel B) were incubated with indicated concentrations of WD5 or N-terminal peptides. Results are presented as a percent of untreated control
###end p 23
###begin title 24
Binding of Tat to LIS1 does not affect the inhibition of PP2A by LIS1
###end title 24
###begin p 25
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
We next analyzed whether Tat has an effect on the inhibition of PP2A by LIS1. Purified recombinant Tat was added to PP2A or PP1 alone or in combination with LIS1 and phosphorylase phosphatase activity of PP2A or PP1 was assayed. Recombinant Tat was expressed in bacteria and purified by reverse phase chromatography as we previously described [27]. Tat inhibited PP1 but not PP2A (Fig. 7, lane 1). LIS1 inhibited the activity of PP2A but not PP1 (Fig. 7, lanes 2 and 3). Addition of Tat to LIS1 did not change the LIS1 inhibition of PP2A (Fig. 7, lanes 4 to 7). Also addition of LIS1 to Tat did not change the inhibition of PP1 by Tat (Fig. 7, lanes 4 to 7). Thus Tat has no effect on LIS1-mediated inhibition of PP2A.
###end p 25
###begin p 26
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LIS1 inhibition of PP2A is not altered by Tat</bold>
LIS1 inhibition of PP2A is not altered by Tat. Phosphatase assay was performed as described in Methods. PP2A (open bars) or PP1 (closed bars) were assayed in the presence of LIS1 and/or Tat. Lane 1, 1 mug of Tat. Lane 2, 0.2 mug of LIS1. Lane 3, 0.4 mug of LIS1. Lane 4, 0.5 mug of Tat and 0.2 mug of LIS1. Lane 5, 0.5 mug of Tat and 0.4 mug of LIS1. Lane 6, 1 mug of Tat and 0.2 mug of LIS1. Lane 7, 1 mug of Tat and 0.4 mug of LIS1.
###end p 26
###begin p 27
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Taken together, our results show that LIS1 upregulates HIV-1 Tat mediated transcription and that this upregulation could be due to the inhibition or modulation of PP2A activity by LIS1.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results presented here show that LIS1 upregulates HIV-1 transcription possibly by inhibiting PP2A. We demonstrate that the WD domains but not the N terminal domain of LIS1 are involved in both upregulation of transcription and PP2A inhibition.
###end p 29
###begin p 30
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 160 165 <span type="species:ncbi:4932">yeast</span>
###xml 361 366 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
LIS1, a microtubule binding protein [28] regulates microtubule dynamics by interacting with dynein motor, NudC and Dynactin [29,30] and also with Nudel [31]. A yeast homologue of LIS1, NudF associates with NudC to regulate dynein and microtubule dynamics [32,33]. Lissencephaly is a neuronal disease caused by a severe mutation in the LIS1 gene. Interestingly, HIV-1-associated dementia is prevalent in the patients with AIDS. Whether there is a connection between deregulation of LIS1 function and development of dementia is not yet known, but obviously this is an intriguing possibility.
###end p 30
###begin p 31
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1113 1122 1113 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1126 1134 1126 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1226 1228 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1518 1520 1518 1520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1521 1523 1521 1523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 339 344 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 753 756 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 803 806 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1497 1502 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2110 2115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2310 2315 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2354 2359 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We envision a possible mechanism of Tat, LIS1 and PP2A interaction (Fig 8). We propose that LIS1 binds PP2A core enzyme and substitutes the B subunit of PP2A holoenzyme. By substituting the targeting B subunit of PP2A, LIS1 may relocate PP2A to a new substrate and also move it away from its physiological substrate (Fig 8). Tat-dependent HIV-1 transcription requires the activity of CDK9, and CDK9 autophosphorylation was shown to be important for the binding of CDK9/cyclin T1 to TAR RNA [34]. As we have recently shown PP2A dephosphorylates CDK9 and pretreatment of CDK9 with PP2A increases CDK9 autophosphorylation [35]. Thus it is possible that Tat might coordinate CDK9 dephosphorylation by PP2A prior to its recruitment to TAR RNA. Activation of CMV promoter by LIS1 supports this explanation as CMV promoter strongly relies on CDK9 activity [36]. The inhibitory effect of LIS1 on PGK promoter indicates that LIS1 might have a differential effect on cellular promoters. Further studies are needed to analyze the effect of LIS1 on cellular gene expression. We previously showed that Tat interacts with LIS1 in vitro and in vivo and that LIS1 was part of a larger complex that in addition contained CDK7, cyclin H, MAT1 [10]. It is possible that interaction of Tat with this complex might activate CDK7 and ultimately affect viral gene expression through a direct activation of CDK7 or indirectly through activation of a down stream kinase, CDK2, which we recently showed to be important for HIV-1 transcription [37,38]. As Tat is shuttling between nucleus and cytoplasm, its interaction with LIS1 and CDK7-containing protein complex might allow a temporary activation of the CDK7 activity. Although LIS1 is a cytoplasmic protein, it is often found in the perinuclear area where the initial assembly of the complex containing CDK7 might take place. Finally, LIS1 may also remove PP2A away from IkappaB, promoting IkappaB phosphorylation by IkappaK and release and activation of NF-kappaB. The liberated NF-kappaB translocates to the nucleus and increases transcription from responsive promoters including HIV-1 LTR. Taken together, there are number of potential pathways that can be affected by LIS1 interaction with PP2A. Further studies are needed to clarify the detailed mechanism of LIS1 induction of HIV-1 transcription and the role of LIS1 in HIV-1 pathogenesis.
###end p 31
###begin p 32
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Proposed mechanism of Tat, LIS1 and PP2Ainteraction</bold>
Proposed mechanism of Tat, LIS1 and PP2Ainteraction. Binding of Tat to LIS1 may rearrange LIS1 binding to microtubules to allow its interaction with PP2A core enzyme.
###end p 32
###begin title 33
Methods
###end title 33
###begin title 34
Materials
###end title 34
###begin p 35
###xml 129 135 <span type="species:ncbi:9986">Rabbit</span>
PP1 was a generous gift from Dr. Bollen (Catholic University of Leuven, Belgium). PP2A was purchased from Upstate (Chicago, IL). Rabbit polyclonal LIS1 antibodies were purchased from Novus Biologicals. Anti-Flag and anti-a-tubulin antibodies were from Sigma.
###end p 35
###begin title 36
Plasmids
###end title 36
###begin p 37
###xml 737 739 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 823 825 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 275 280 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 295 300 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 528 531 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 618 626 <span type="species:ncbi:9606">Children</span>
The HIV-1 reporter contained HIV-1 LTR (-138 to +82) followed by a nuclear localization signal (NLS) and the LacZ reporter gene (courtesy of Dr. Michael Emmerman, Fred Hutchinson Cancer Institute, Seattle, WA). It expresses NLS-tagged beta-galactosidase under the control of HIV-1 LTR (16). The HIV-1 reporter plasmid without TAR contained a deletion of +19 to +87 nucleotides of LTR introduced by restriction digestion with BglII. The Tat expression plasmid was a gift from Dr. Ben Berkhout (University of Amsterdam) (17). The CMV-EGFP cloned into the Adenovirus shuttle vector was a gift from Dr. Marina Jerebtsova (Children's National Medical Center). The SIN vector containing phosphoglycerol kinase (PGK) promoter followed by EGFP [39] was a gift from Dr. John Tisdale (NIDDK, NIH). The PP2A Bgamma expression vector [24] was a gift from Dr. Stefan Strack (University of Iowa).
###end p 37
###begin title 38
Expression and purification of WD5 and N terminal of LIS1
###end title 38
###begin p 39
###xml 204 206 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">r </sup>
###xml 381 394 381 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli BL21 </italic>
###xml 381 393 <span type="species:ncbi:511693">E. coli BL21</span>
The DNA sequences encoding each of the seven WD domains and the amino terminal domain of LIS1 were subcloned into a plasmid carrying T7 promoter upstream of the multiple cloning site and a myc tag and ampr markers. These vectors were created at the laboratory of Dr. Orly Reiner (The Weizmann Institute of Science, Israel) and were kindly given to us. The DNA was transformed into E. coli BL21 SI cells. The cells were grown to mid log phase, and synthesis of recombinant proteins was induced by the addition of NaCl to a final concentration of 0.3M for 18 hours according to the recommendation of manufacturer (Invitrogen). The cells were lysed by sonication in a buffer A (10 mM Tris-HCl (pH 7.8), 50 mM NaCl, 1 mM EDTA 1 mM PMSF, 20% glycerol) and inclusion bodies were recovered by centrifugation. Inclusion bodies were dissolved in the buffer A containing additionally 6M urea and proteins were concentrated on microcone spinning tubes (Millipore, Billerica, MA). The recombinant proteins were dialyzed against PBS before usage.
###end p 39
###begin title 40
Cell culture and transfection
###end title 40
###begin p 41
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Cells were maintained in Dubelco Modified Eagles Medium (DMEM) supplemented with 10% FBS and 0.1%penicillin/streptomycin. HEK293 cells were subcultured 24 hrs prior to transfection to achieve 60% confluence on the day of transfection. Transfections were carried out in 96 well plates and in some experiments in 6 well plates. Transfections were performed by calcium phosphate precipitation as previously described [40].
###end p 41
###begin title 42
Subcloning of pCI-LIS
###end title 42
###begin p 43
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
LIS1 gene was subcloned from pAGA2 vector [10] to pCI-Neo eukaryotic expression vector (Promega, Madison, WI). The pAGA2-LIS1 plasmid was digested with EcoR1 and Sal1 to extract LIS1 fragment. The LIS1-containig DNA fragment was purified on the agarose gel and ligated into the pCI-Neo digested with EcoR1 and Sal1. The resulting plasmid pCI-LIS was checked by restriction digestion with EcoR1 and Sal1 to visualize ligation products on an agarose gel and also by sequencing with T7 and T3 primers.
###end p 43
###begin title 44
beta-galactosidase assay
###end title 44
###begin p 45
###xml 225 227 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 519 520 511 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 522 524 514 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 559 560 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 721 722 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 724 725 715 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HEK 293 cells transfected with HIV-1 LTR-LacZ and HIV-1 Tat expression vectors were lyzed and the level of transcription from the HIV-1 LTR was determined by measuring the beta-galactosidase activity as previously described [40]. Briefly, cells were washed with phosphate-buffered saline (PBS) and lysed for 20 min at room temperature in 50 mul of lysis buffer, containing 20 mM HEPES at pH 7.9, 0.1% Nonidet P-40, and 5 mM EDTA. Subsequently, 100 mul of o-nitrophenyl-beta-D-galactopyranoside (ONPG) solution (72 mM Na2PO4 at pH 7.5, 1 mg/ml ONPG, 12 mM MgCl2, 180 mM 2-mercaptoethanol) was added and incubated at room temperature until a yellow color developed. The reaction was stopped by addition of 100 mul of 1 M Na2CO3. The 96-well plates were analyzed in a micro plate reader at 414 nm (Lab Systems Multiscan MS). The beta-galactotosidase units were calculated using a linear graph plotted from optical density (OD) readings of the standard.
###end p 45
###begin title 46
Florescence measurement
###end title 46
###begin p 47
293T cells transfected in 96-well plate were lysed in 50 mul of lysis buffer per well (20 mM HEPES at pH 7.9, 0.1% Nonidet P-40, and 5 mM EDTA), then supplemented with 150 mul of PBS and transferred to fluorescent-compatible 96-well plate. The GFP fluorescence was measured at 480 nm excitation and 510 nm emission on Luminescence Spectrometer LS50B (Perkin-Elmer) equipped with the robotic 96-well scanner.
###end p 47
###begin title 48
Western blot
###end title 48
###begin p 49
Cells transfected with various vectors were washed 3 times with PBS and then lyzed with lysis buffer containing 50 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1% NP-40, 0.1% SDS and protease inhibitor cocktail (Sigma). The control cell extracts were prepared from mock-transfected 293T cells. About 5 mug whole cell extract proteins were resuspended in a 30 mul of 1x SDS loading buffer (4% SDS, 10% glycerol, 5% 2-mecarpthaethanol, 0.002% bromophenol blue) and heated at 90degreesC for 3 minutes. The proteins were resolved on 10% SDS Polyacrylamide gel electrophoresis (PAGE) and immunoblotted with anti-LIS1 or anti tubulin antibodies
###end p 49
###begin title 50
Phosphatase assay
###end title 50
###begin p 51
###xml 14 16 14 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 99 101 99 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a </italic>
###xml 326 328 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Phosphorylase-a was prepared as previously described [26]. Approximately 0.2 nmol of phosphorylase-a was used as a substrate for PP1 or PP2A. The phosphorylase phosphatase assay was carried out for 10 min in a buffer containing 50 mM glycylglycine at pH 7.4, 0.5 mM dithiothreitol, and 5 mM beta-mercaptoethanol as described [41]. Where indicated, prior to the phosphorylase phosphatase assay, the samples were trypsinized to generate free, active catalytic subunit of PP1.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The author(s) declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
NE created LIS1 expression vector, purified WD5 and N-terminal peptides, and conducted transfection experiments and some of the phosphatase inhibition assays. TA prepared phosphorylase-a and helped to conduct phosphatase assays. WT participated in the design and discussion of the study. SN performed general control and coordination of the study. All authors read and approved the manuscript.
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
###xml 662 670 <span type="species:ncbi:9606">Children</span>
This work was supported by NIH Research Grant # UH1 HL03679 funded by National Heart, Lung and Blood Institute and The Office of Research on Minority Health; and by grant AI056973. The pGEM2Tat bacterial expression vector was provided by Richard Gaynor and obtained through the NIH AIDS Research and Reference Reagents Program, Division of AIDS, NIAID, NIH. We would like to thank Dr. Victor Gordeuk and members of the Research Scientist Laboratory for their suggestions and discussion. We would like to thank Orly Reiner (The Weizmann Institute of Science, Israel), Mathieu Bollen and Monique Beullens (Catholic University, Leuven, Belgium), Marina Jerebtsova (Children's National Medical Center), John Tisdale (NIDDK, NIH) and Stefan Strack (University of Iowa) for the gift of reagents.
###end p 57
###begin article-title 58
Tat gets the "green" light on transcription initiation
###end article-title 58
###begin article-title 59
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat transcriptional activity is regulated by acetylation
###end article-title 59
###begin article-title 60
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity
###end article-title 60
###begin article-title 61
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones
###end article-title 61
###begin article-title 62
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The Tat protein of the human immunodeficiency virus type 1 (HIV-1) interacts with the EGF-like repeats of the Notch proteins and the EGF precursor
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin-signaling through CREB
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim
###end article-title 64
###begin article-title 65
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 143 148 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Neuronal apoptosis induced by HIV-1 Tat protein and TNF-alpha: potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia
###end article-title 65
###begin article-title 66
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat protein enhances microtubule polymerization
###end article-title 66
###begin article-title 67
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat interacts with LIS1 protein
###end article-title 67
###begin article-title 68
Lissencephaly and subcortical band heterotopia: molecular basis and diagnosis
###end article-title 68
###begin article-title 69
Lissencephaly gene (LIS1) expression in the CNS suggests a role in neuronal migration
###end article-title 69
###begin article-title 70
The ancient regulatory-protein family of WD-repeat proteins
###end article-title 70
###begin article-title 71
Signaling by protein phosphatases in the nucleus
###end article-title 71
###begin article-title 72
###xml 72 78 <span type="species:ncbi:9986">rabbit</span>
###xml 83 90 <span type="species:ncbi:8355">Xenopus</span>
Analysis of subunit isoforms in protein phosphatase 2A holoenzymes from rabbit and Xenopus
###end article-title 72
###begin article-title 73
The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm
###end article-title 73
###begin article-title 74
The third subunit of protein phosphatase 2A (PP2A), a 55-kilodalton protein which is apparently substituted for by T antigens in complexes with the 36- and 63-kilodalton PP2A subunits, bears little resemblance to T antigens
###end article-title 74
###begin article-title 75
An anchoring factor targets protein phosphatase 2A to brain microtubules
###end article-title 75
###begin article-title 76
A developmentally regulated, neuron-specific splice variant of the variable subunit Bbeta targets protein phosphatase 2A to mitochondria and modulates apoptosis
###end article-title 76
###begin article-title 77
Comparison of heterotrimeric protein phosphatase 2A containing different B subunits
###end article-title 77
###begin article-title 78
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Increasing the ratio of PP2A core enzyme to holoenzyme inhibits Tat-stimulated HIV-1 transcription and virus production
###end article-title 78
###begin article-title 79
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate
###end article-title 79
###begin article-title 80
###xml 37 72 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat
###end article-title 80
###begin article-title 81
Protein phosphatase 2A holoenzyme assembly: identification of contacts between B-family regulatory and scaffolding A subunits
###end article-title 81
###begin article-title 82
Okadaic acid, useful tool for studying cellular processes
###end article-title 82
###begin article-title 83
Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II
###end article-title 83
###begin article-title 84
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 155 160 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter
###end article-title 84
###begin article-title 85
LIS1 is a microtubule-associated phosphoprotein
###end article-title 85
###begin article-title 86
###xml 33 53 <span type="species:ncbi:162425">Aspergillus nidulans</span>
The LIS1-related protein NUDF of Aspergillus nidulans and its interaction partner NUDE bind directly to specific subunits of dynein and dynactin and to alpha- and gamma-tubulin
###end article-title 86
###begin article-title 87
A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function
###end article-title 87
###begin article-title 88
NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein
###end article-title 88
###begin article-title 89
###xml 46 51 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of the human NUDC gene
###end article-title 89
###begin article-title 90
###xml 30 35 <span type="species:ncbi:9606">human</span>
Nudf, a fungal homolog of the human LIS1 protein, functions as a dimer in vivo
###end article-title 90
###begin article-title 91
###xml 64 99 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA
###end article-title 91
###begin article-title 92
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription
###end article-title 92
###begin article-title 93
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II
###end article-title 93
###begin article-title 94
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
RNA interference directed to CDK2 inhibits HIV-1 transcription
###end article-title 94
###begin article-title 95
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antiviral activity of CYC202 in HIV-1-infected cells
###end article-title 95
###begin article-title 96
Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy
###end article-title 96
###begin article-title 97
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nuclear protein phosphatase-1 regulates HIV-1 transcription
###end article-title 97
###begin article-title 98
###xml 77 83 <span type="species:ncbi:9913">bovine</span>
The isolation of novel inhibitory polypeptides of protein phosphatase 1 from bovine thymus nuclei
###end article-title 98

